Adaptive Biotechnologies Corporation · NASDAQ:ADPT
Adaptive Biotechnologies — Q1 2021 Earnings Presentation
13 slides from Adaptive Biotechnologies's earnings presentation, 2021
Slide 1: First Quarter 2021 Earnings Conference Call
First Quarter 2021 Earnings Conference Call
Slide 2: Safe Harbor
Safe Harbor This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements co
Slide 3: Q1 2021 Key Highlights
Q1 2021 Key Highlights T-Detect COVID: granted EUA by the FDA to confirm COVID-19 past infection ✓ . ✓ .T-Detect GI: Crohn’s data results confirm signal and show distinction from colitis ✓ .MRD pharma portfolio: monetized 2 milestones; added Pfizer MRD partnership Strong Revenues Q1’21 $38.4M ✓ .imm
Slide 4: T-Detect Franchise, COVID sets the stage for future indications
T-Detect Franchise, COVID sets the stage for future indications T-Detect COVID available Strategic value for franchise ◼ Granted EUA by FDA to confirm SARS-CoV-2 ◼ R&D acceleration past infection ❑ FDA authorized 1st T-cell test ❑ Validation of T-cell based assay CLINICAL DIAGNOSTICS ◼ >3,000 tests
Slide 5: T-Detect: building towards the future
T-Detect: building towards the future Accelerating Differential Diagnostic approach 1 2 3 Improve SOC Dx Differential Diagnosis Population Immunomics Disease by disease Diseases with shared symptoms Any mapped disease T-Detect T-Detect T-Detect GI Aspirational long-term COVID Lyme vision ◼ Launched
Slide 6: T-Detect GI, Crohn's data supports differential diagnostic approach
T-Detect GI, Crohn’s data supports “differential diagnostic approach” Distinct TCR signatures confirm innate specificity of T cells Crohn’s classifier (99% specificity, COVID-19 classifier (100% specificity, initial sensitivity of >70%) current sensitivity of 97%) (1,000+ distinct ileal (thousands d
Slide 7: clonoSEQ brand, strong clinical adoption and robust pharma partnerships
clonoSEQ brand, strong clinical adoption and robust pharma partnerships clonoSEQ clinical MRD Pharma Partners ◼ Q1’21 test delivered volume +35% vs P/Y; +6% vs P/Q ◼ Strong sequencing revenue growth Q/Q LIFE SCIENCES RESEARCH CLINICAL DIAGNOSTICS ❑ 231 ordering accounts and 825 ordering HCPs in Q1 ◼
Slide 8: Life Sciences Research, off to a good start
Life Sciences Research, off to a good start … Strong growth from Research revenues >80% vs prior year ◼ Strong pharma research growth with new bookings continuing to increase ◼ Academic had a slow start due to lingering COVID impact, but recent orders trending above pandemic levels. ◼ RUO kit: train
Slide 9: Focus on next shared product and scaling private product development
Focus on next shared product and scaling private product development Shared Product Private Product ◼ 1st Shared Product suspended by GNE ◼ Completed initial proof of concept on 15 cancer patients ❑ New data showed expression of antigen target in healthy tissue ❑ Screened blood from cancer patients
Slide 10: Q1 2021 Key Financial Highlights
Q1 2021 Key Financial Highlights Revenues ($M) Operating Expenses2 ($M) Sequencing $38.4 +84% Development $79.3 +60% +44% 15.2 $55.1 $20.9 9.5 1 23.3 +103% 11.4 Q1 2020 Q1 2021 Q1 2020 Q1 2021 1 Includes $7M in MRD milestones 2 Exclude amortization of intangible assets Sequencing Volume Balance Shee
Slide 11: 2021 Catalysts
2021 Catalysts ✓ Embed T-MAP COVID into SARS-CoV-2 vaccine trials Life Science ◼ Expand immunoSEQ T-MAP data offering into other disease categories Research ◼ Expand distribution of immunoSEQ RUO kit ✓ T-Detect COVID EUA granted by FDA; commercialization Clinical ◼ FDA clearance for clonoSEQ ALL in
Slide 12: Thank You.
Thank You.
Slide 13: Appendix: Clinical portfolio and pipeline
Appendix: Clinical portfolio and pipeline Diagnostic Signal Clinical FDA FDA Product Plan Discovery Validation Submission Clearance Multiple Myeloma Acute Lymphoblastic Leukemia Monitor MRD: Chronic Lymphocytic Leukemia Non-Hodgkin’s Lymphoma (Subtypes)1 COVID-192 (EUA) Accurate Detection: Lyme Dise
Adaptive Biotechnologies — Q1 2021 Earnings Presentation on 6ix